Recombinant Human CD223
Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Recombinant Human CD223
category
Proteins and Peptides
provider
FineTest
reference
P1753
tested applications
Western Blot, ELISA
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | 23-222 |
| Host | E.Coli |
| Origin | Human |
| Observed MW | 42.5 kDa |
| Expression | Recombinant |
| Purity | Greater than 95% by SDS-PAGE gel analyses |
| Purification | IF2DI tag |
| Size 1 | 50μg |
| Size 2 | 200μg |
| Size 3 | 1mg |
| Form | Lyophilized from a 0.2um filtered solution in PBS with 5% trehalose, pH7.4 |
| Tested Applications | Western Blot, ELISA |
| Buffer | Reconstitute with Sterile distilled water |
| Availability | 7 days |
| Storage | -20°C for 12 months as lyophilized;2-8°C for 1 month under sterile conditions after reconstitution |
| UniProt ID | P18627 |
| Alias | Lymphocyte activation gene 3 protein ,CD223,LAG-3,FDC |
| Background | Proteins LAG3 |
| Status | RUO |
| Note | This product is for research use only. |
LAG3 (lymphocyte-activation gene 3), also known as CD223, is a cell surface protein that plays a critical role as an immune checkpoint inhibitor. It functions as a negative regulator of T cell activity and is predominantly expressed on activated T cells, regulatory T cells (Tregs), and natural killer (NK) cells. LAG-3 belongs to the immunoglobulin (Ig) superfamily and is structurally similar to CD4, although it performs an inhibitory rather than activating function. Its primary ligand is the major histocompatibility complex (MHC) class II, and it binds with much higher affinity than CD4, providing it with strong immunoregulatory capabilities. As an immune checkpoint receptor, LAG-3 is critical for maintaining immune homeostasis and preventing autoimmune reactions by moderating immune responses. Its expression is upregulated during chronic infections and in cancer, often contributing to T cell exhaustion, a state in which T cells progressively lose function due to prolonged antigen exposure. This makes LAG-3 a therapeutic target in immuno-oncology and chronic infection therapies. The blockade of LAG-3 has shown potential in restoring T cell function, thereby enhancing anti-tumor and anti-pathogen immune responses.
Related Products
Human LAG3(Lymphocyte activation gene 3 protein) ELISA Kit
Ver Producto
anti- LAG-3 antibody
Ver Producto